

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification by replacing the paragraph on page 3, lines 13-22, with the following paragraph:

Based on these results, it has now been found that a medicament is effective against thrombotic diseases if it comprises an active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes. This active principle may be a chemical compound or a monoclonal or polyclonal antibody. A preferred monoclonal antibody is JAQ1 and the preferred collagen receptor is platelet GPVI. If the monoclonal antibody JAQ1 is used it should be a humanized monoclonal antibody JAQ1. The hybridoma cell line secreting JAQ1 ~~has been~~ was deposited on December 20, 2000, under Accession No. DSM ACC 2487 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany, in Braunschweig in accordance with the Budapest Treaty.